Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...